Clostridium Difficile Infections (Clostridium Difficile Associated Disease) – Pipeline Review, 2019

Clostridium difficile, also referred to as C. difficile or C. diff is a bacterium that can induce a range of symptoms including diarrhea to the life-threatening inflammation of the colon. Clostridium difficile infections generally occur in elderly adults residing in hospitals or in long term care facilities and typically occurs after the administration of antibiotic medications. Recent studies have shown the increased risk of clostridium difficile infections in younger and healthy populations without any prior history of exposure to healthcare institutions or antibiotic usage.

Some of the symptoms associated with clostridium difficile infections include diarrhea of more than 10 times a day, severe abdominal cramping, fever, loss of appetite, dehydration and rapid heartbeat. The diagnosis of clostridium difficile is often undertaken with stool tests which include enzyme immunoassay, polymerase chain reaction and cell cytotoxicity assays. The treatment of these infections is often conducted by the administration of antibiotics such as metronidazole, vancomycin, and fidaxomicin.

Pharmaceutical companies along with various research institutes have been focusing on studying and developing new treatment options for clostridium difficile infections (clostridium difficile associated disease). For instance; RBX2660, which is being studied by Rebiotix Inc., is currently in phase-3 clinical trials for the microbiota restoration therapy for recurrent clostridium difficile infection (PUNCH CD3-OLS) (CD3-OLS).

To know how our report can help streamline your business, Speak to Analyst

At present around 75% of the pipeline candidates for clostridium difficile infections (clostridium difficile associated disease) are in the phase-2 and phase-3 stage combined. More than half of the studies are sponsored by industry.

Report Description

The report on ‘Clostridium Difficile Infections (Clostridium Difficile Associated Disease) – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Clostridium Difficile Infections (Clostridium Difficile Associated Disease).

The report on ‘Clostridium Difficile Infections (Clostridium Difficile Associated Disease) – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Clostridium Difficile Infections (Clostridium Difficile Associated Disease)


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players in relation to R&D for Clostridium Difficile Infections (Clostridium Difficile Associated Disease)


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary